Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Lobeglitazone Monotherapy in Type 2 Diabetes
NCT01001611Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lobeglitazone in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang Holdings. Started Oct 2009; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01001611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001611.